An interventional study of Physical touch in Depression, sponsored by Yale University. Not yet recruiting at 1 site in United States. Open to female participants aged 21 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Yale University · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Depression by Yale University — 7 open to participants now, 9 under way, 1 of them phase 3. Depression · Yale University.
Among the 60 studies in Depression by Yale University, this one is the 25th largest by planned enrollment of the 52 interventional ones that give a count, is one of 3 that started in 2026, is one of 35 with no phase, and was the 60th registered.
8,582 studies on the registry are indexed under Depression; 1,723 are open to participants now.
Browse Depression studies →7 of the 60 studies in Depression by Yale University are open now, in 2 countries. Recruiting first, the newest first:
Yale University · Sites in Uganda
Ages 18+
Yale University · Sites in United States
Ages 40–80
Yale University · Sites in United States
Ages 18+
Yale University · Sites in United States
Ages 18–68 · Healthy volunteers
Yale University · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 1,089 Depression studies recruiting now, 470 (43%) set no upper age limit and 519 (48%) stop at 75 or younger; 203 take children under 18; 311 take healthy volunteers.
This study: 21 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 6 · Phase 3 4 · Phase 4 1
First in 2001; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 81 across 7,066 interventional studies indexed under Depression.
Median enrollment 51 across the 52 interventional studies, 124 across the 8 observational. Of the 51 that completed or were terminated, 17 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
Yale University is the lead sponsor of 1,772 studies on the registry; 296 are open to participants now.
Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.
2 of the studies in Depression by Yale University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02734602Yale UniversityImaging SV2A in Mood Disorders | 2027-01 |
| NCT05810259Yale UniversityAssessing the Effectiveness of Digital Wellness Modules on Perceived Quality of Life | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 60 studies in Depression by Yale University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to learn more about mother-infant interactions, including how infants experience different types of touch.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All infant participants will receive CT-optimal touch, non-CT optimal touch, and no stroking touch condition
Other: Physical touch
All infant participants will receive CT-optimal touch, non-CT optimal touch, and no stroking touch condition
Infant heart-evoked potentials
The amplitude of infant heart-evoked potentials will be examined as a function of the experimental touch condition (CT optimal touch, non-CT optimal touch, and non stroking touch).
Time frame: During experimental task on the study visit day (1 day)
Infant heart rate
Infant heart rate will be examined as a function of the experimental touch condition (CT optimal touch, non-CT optimal touch, and non stroking touch).
Time frame: During experimental task on the study visit day (1 day)
Plan to share: Yes — IPD to be shared (all de-identified): Infant EEG and ECG Data Maternal Self-Reported Questionnaire and Interview Data Quantitative scores from behavioral coding of video recordings of infants and mother-infant interactions Infant tactile sensitivity
Time frame: At the time of publication
Access criteria: Data will be made available on OpenNeuro and Open Science Framework
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Aug 2028, 20 months later.
Of 3,471 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 20 months is close to that.
Counting every sponsor, half of 3,569 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.